Related Experiment Videos
Human defensins in Crohn's disease
Jan Wehkamp1, Klaus Fellermann, Eduard F Stange
1Department of Microbiology and Immunology, University of California, Davis, Calif., USA.
Chemical Immunology and Allergy
|June 25, 2005
Summary
Reduced mucosal peptide antibiotics, like defensins, may drive Crohn's disease. This is particularly evident in ileal Crohn's disease, especially with NOD2 gene mutations, indicating impaired gut defense.
Area of Science:
- Gastroenterology
- Immunology
- Microbiology
Background:
- Crohn's disease involves gut inflammation, potentially linked to hygiene, antibiotics, and bacterial interactions.
- A breakdown in tolerance to gut bacteria and reduced mucosal peptide antibiotics are implicated in Crohn's disease pathogenesis.
- The adaptive immune system's dysregulation might stem from a primary failure in mucosal defense against luminal bacteria.
Purpose of the Study:
- To investigate the role of mucosal antibacterial activity in Crohn's disease.
- To compare defensin expression in Crohn's disease patients with and without ileal involvement.
- To examine the influence of NOD2 gene mutations on defensin expression in ileal Crohn's disease.
Main Methods:
- Comparative analysis of ileal Paneth cell defensin expression in Crohn's disease patients and controls.
- Assessment of defensin expression in relation to ileal involvement and NOD2 gene mutations.
- Evaluation of human beta defensin 2 and 3 induction in colonic Crohn's disease versus ulcerative colitis.
Main Results:
- Crohn's disease patients with ileal involvement show diminished ileal Paneth cell defensin expression compared to controls.
- This reduction in defensins is more pronounced in Crohn's disease patients with NOD2 gene mutations.
- Impaired induction of human beta defensins 2 and 3 is observed in colonic Crohn's disease, unlike ulcerative colitis.
Conclusions:
- A decrease in mucosal peptide antibiotics, specifically Paneth cell defensins, is a key feature of ileal Crohn's disease.
- NOD2 mutations exacerbate this impaired mucosal defense in Crohn's disease.
- These findings support the hypothesis of compromised mucosal antibacterial activity in Crohn's disease, potentially explaining treatment benefits from antibiotics or probiotics.